GenSight Biologics S.A. (GSGTF)
- Previous Close
3.1000 - Open
0.4800 - Bid --
- Ask --
- Day's Range
0.4500 - 0.4500 - 52 Week Range
0.0003 - 0.7550 - Volume
756 - Avg. Volume
3 - Market Cap (intraday)
44.566M - Beta (5Y Monthly) 2.30
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6000 - Earnings Date Sep 23, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. It has license agreements with Sorbonne Université, CNRS, Inserm and SATT Lutech; Inserm Transfert S.A, Genethon, and Harvard; Massachusetts Institute of Technology; Novartis Pharma AG; Sorbonne University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale and Satt Lutech; Association Fran?aise contre les Myopathies, Inserm Transfert S.A; and non-exclusive license agreement with Adverum Biotechnologies. The company was incorporated in 2012 and is headquartered in Paris, France.
www.gensight-biologics.comRecent News: GSGTF
View MorePerformance Overview: GSGTF
Trailing total returns as of 9/23/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GSGTF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GSGTF
View MoreValuation Measures
Market Cap
32.49M
Enterprise Value
50.67M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.98
Price/Book (mrq)
--
Enterprise Value/Revenue
35.84
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-105.83%
Return on Equity (ttm)
--
Revenue (ttm)
2.96M
Net Income Avi to Common (ttm)
-26.22M
Diluted EPS (ttm)
-0.6000
Balance Sheet and Cash Flow
Total Cash (mrq)
2.13M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-14.13M
Company Insights: GSGTF
GSGTF does not have Company Insights